There is strong evidence suggesting the presence of HLA-DRB1 allele shared epitope as a risk factor for anti-cyclic citrullinated peptide (CCP) antibody development. Rheumatoid factor (RF) and anti-CCP positivity are associated with an increased risk of development of extraarticular RA (ExRA).